MicroPort Scientific's (HKG:0853) subsidiary Shanghai MicroPort Endovascular MedTech (Group) (SHE:688016) expects to book net profit attributable to equity owners between 492.5 million yuan and 541.0 million yuan for 2024, 0.01% to 9.86% higher than the preceding year, a Monday Hong Kong bourse filing said.
The expected increase was attributed to an increase in overseas revenue and the number of Hospitals entered by Shanghai MicroPort Endovascular MedTech, a continued momentum contributed by its products, and an increase in the number of terminal implants for its new products during the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.